Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Thomas R. Blue"'
Autor:
Michael S. Gordon, Thomas R. Blue, Frank J. Vocci, Shannon G. Mitchell, Kevin R. Wenzel, Marc Fishman
Publikováno v:
Drug and Alcohol Dependence Reports, Vol 12, Iss , Pp 100261- (2024)
Background: Buprenorphine maintenance treatment remains unavailable in most jails in the US. We provide data on a four-day rapid sublingual buprenorphine (SL-B) induction strategy followed by a weekly dose of extended-release injectable buprenorphine
Externí odkaz:
https://doaj.org/article/917ac301ba624ac2b2b749f3d9264294
Autor:
Thomas R. Blue, Michael S. Gordon, Robert P. Schwartz, Kathryn Couvillion, Frank J. Vocci, Terrence T. Fitzgerald, Kevin E. O’Grady
Publikováno v:
Addiction Science & Clinical Practice, Vol 14, Iss 1, Pp 1-11 (2019)
Abstract Background It has been estimated that approximately 15% of people who are incarcerated in the US have histories of opioid use disorder. Relapse to opioid use after release from prison poses a serious risk of HIV infection. Prison-initiated b
Externí odkaz:
https://doaj.org/article/af5c80c2ac184096ae0b2f232f790460
Autor:
Wayne E.K. Lehman, Jennifer Pankow, Grace A. Rowan, Julie Gray, Thomas R. Blue, Roxanne Muiruri, Kevin Knight
Publikováno v:
Contemporary Clinical Trials Communications, Vol 10, Iss , Pp 86-93 (2018)
This paper describes the development and protocol for feasibility and efficacy testing of a risk reduction intervention designed to improve behavioral health outcomes among drug offenders on probation under community supervision or in residential sub
Externí odkaz:
https://doaj.org/article/5996acf54747496cb675bc5330bcf2a3
Autor:
Fanni Farago, Thomas R. Blue, Lindsay Renee Smith, James C. Witte, Michael Gordon, Faye S. Taxman
Publikováno v:
Journal of Drug Issues. 53:296-320
Problem-solving courts (PSCs) are a critical part of a societal effort to mitigate the opioid epidemic's devastating consequences. This paper reports on a national survey of PSCs (N = 42 state-wide court coordinators; N = 849 local court coordinators
Autor:
Thomas R. Blue, Frank Vocci, Bikash Sharma, Faye S. Taxman, Marc Fishman, Michael S. Gordon, Kevin E. O'Grady
Publikováno v:
Contemporary Clinical Trials. 79:21-27
Background Buprenorphine can be effective in a variety of community substance use treatment settings outside of methadone programs, including outpatient programs and medical practices. In these settings, it has been found to be effective in reducing
Publikováno v:
J Offender Rehabil
Many criminal justice-involved persons on probation or parole do not receive HIV testing despite being at an increased risk for infection and transmission. Between April, 2011 and May, 2012 in Baltimore, MD and Providence, RI, a two-group randomized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f91ac5a099f590636c0c8f3d9aec83e
https://europepmc.org/articles/PMC10195011/
https://europepmc.org/articles/PMC10195011/
Publikováno v:
J Acquir Immune Defic Syndr
BACKGROUND Evidence-based interventions that engage community-dwelling, justice-involved, people living with HIV (PLWH) in care are urgently needed. Project Bridge, an intensive case management intervention, has demonstrated efficacy for linking PLWH
Autor:
Martha L. Danner, Daniel K. Jarvis, Kevin Wenzel, Thomas R. Blue, Kathy Couvillion, Michael S. Gordon, Shannon Gwin Mitchell, Frank Vocci, Kelly Maher, Sean M. Murphy, Danielle A. Ryan, Marc Fishman
Publikováno v:
J Subst Abuse Treat
This study is a randomized, open label, controlled trial of extended-release buprenorphine (XR-B; BRIXADI(™) formulation) versus extended-release naltrexone (XR-NTX) in Maryland jails. A 7-site, open-label, equivalence design will randomly assign 2
Autor:
Frank Vocci, Kevin E. O'Grady, Robert P. Schwartz, Thomas R. Blue, Terrence T. Fitzgerald, Michael S. Gordon, Kathryn A. Couvillion
Publikováno v:
Addiction Science & Clinical Practice
Addiction Science & Clinical Practice, Vol 14, Iss 1, Pp 1-11 (2019)
Addiction Science & Clinical Practice, Vol 14, Iss 1, Pp 1-11 (2019)
Background It has been estimated that approximately 15% of people who are incarcerated in the US have histories of opioid use disorder. Relapse to opioid use after release from prison poses a serious risk of HIV infection. Prison-initiated buprenorph
Autor:
Thomas R. Blue, Jennifer Pankow, Julie Gray, Kevin Knight, Grace A. Rowan, Wayne E. K. Lehman, Roxanne Muiruri
Publikováno v:
Contemporary Clinical Trials Communications, Vol 10, Iss, Pp 86-93 (2018)
Contemporary Clinical Trials Communications
Contemporary Clinical Trials Communications
This paper describes the development and protocol for feasibility and efficacy testing of a risk reduction intervention designed to improve behavioral health outcomes among drug offenders on probation under community supervision or in residential sub